{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Naloxone : Questions médicales les plus fréquentes",
"headline": "Naloxone : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Naloxone : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-09",
"dateModified": "2025-05-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Naloxone"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Morphinanes",
"url": "https://questionsmedicales.fr/mesh/D009019",
"about": {
"@type": "MedicalCondition",
"name": "Morphinanes",
"code": {
"@type": "MedicalCode",
"code": "D009019",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.723.795"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Naltrexone",
"alternateName": "Naltrexone",
"url": "https://questionsmedicales.fr/mesh/D009271",
"about": {
"@type": "MedicalCondition",
"name": "Naltrexone",
"code": {
"@type": "MedicalCode",
"code": "D009271",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.723.795.706.550"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Naloxone",
"alternateName": "Naloxone",
"code": {
"@type": "MedicalCode",
"code": "D009270",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Alexander Y Walley",
"url": "https://questionsmedicales.fr/author/Alexander%20Y%20Walley",
"affiliation": {
"@type": "Organization",
"name": "Boston Medical Center and Boston University School of Medicine, Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, 801 Massachusetts Ave, 2nd Floor, Boston, MA 02118, USA."
}
},
{
"@type": "Person",
"name": "Traci C Green",
"url": "https://questionsmedicales.fr/author/Traci%20C%20Green",
"affiliation": {
"@type": "Organization",
"name": "The Heller School for Social Policy and Management at Brandeis University, Institute for Behavioral Health, 415 South St, MS 035, Waltham, MA 02453, USA."
}
},
{
"@type": "Person",
"name": "Lucas G Hill",
"url": "https://questionsmedicales.fr/author/Lucas%20G%20Hill",
"affiliation": {
"@type": "Organization",
"name": "College of Pharmacy, The University of Texas at Austin, Austin, TX, USA."
}
},
{
"@type": "Person",
"name": "Kirk E Evoy",
"url": "https://questionsmedicales.fr/author/Kirk%20E%20Evoy",
"affiliation": {
"@type": "Organization",
"name": "College of Pharmacy, The University of Texas at Austin, Austin, TX, USA."
}
},
{
"@type": "Person",
"name": "John Strang",
"url": "https://questionsmedicales.fr/author/John%20Strang",
"affiliation": {
"@type": "Organization",
"name": "National Addiction Centre, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, SE5 8BB, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The research escape hunt: An escape room-scavenger hunt for resident education.",
"datePublished": "2022-12-20",
"url": "https://questionsmedicales.fr/article/36562029",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/aet2.10833"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hunting for Answers: Assessing",
"datePublished": "2024-03-08",
"url": "https://questionsmedicales.fr/article/38535585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/pathogens13030242"
}
},
{
"@type": "ScholarlyArticle",
"name": "An eternal hunt for glaucoma.",
"datePublished": "2024-06-03",
"url": "https://questionsmedicales.fr/article/38829407",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00417-024-06441-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Virological non-suppression among adult males attending HIV care services in the fishing communities in Bulisa district, Uganda.",
"datePublished": "2023-10-19",
"url": "https://questionsmedicales.fr/article/37856568",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0293057"
}
},
{
"@type": "ScholarlyArticle",
"name": "Spatial-temporal variation of marine fishing activities responding to policy and social events in China.",
"datePublished": "2023-10-14",
"url": "https://questionsmedicales.fr/article/37844402",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jenvman.2023.119321"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures aromatiques polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011084"
},
{
"@type": "ListItem",
"position": 4,
"name": "Phénanthrènes",
"item": "https://questionsmedicales.fr/mesh/D010616"
},
{
"@type": "ListItem",
"position": 5,
"name": "Morphinanes",
"item": "https://questionsmedicales.fr/mesh/D009019"
},
{
"@type": "ListItem",
"position": 6,
"name": "Naloxone",
"item": "https://questionsmedicales.fr/mesh/D009270"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Naloxone - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Naloxone",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Naloxone",
"description": "Comment diagnostiquer une surdose d'opioïdes ?\nQuels tests sont utilisés pour confirmer une surdose ?\nQuels signes indiquent une surdose d'opioïdes ?\nQuand utiliser la naloxone en cas de surdose ?\nLa naloxone est-elle efficace pour tous les opioïdes ?",
"url": "https://questionsmedicales.fr/mesh/D009270?mesh_terms=Hunting&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Naloxone",
"description": "Quels sont les symptômes d'une surdose d'opioïdes ?\nComment reconnaître une dépression respiratoire ?\nQuels sont les effets secondaires de la naloxone ?\nLa naloxone provoque-t-elle des effets immédiats ?\nQuels signes indiquent que la naloxone fonctionne ?",
"url": "https://questionsmedicales.fr/mesh/D009270?mesh_terms=Hunting&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Naloxone",
"description": "Comment prévenir les surdoses d'opioïdes ?\nLa naloxone est-elle disponible sans ordonnance ?\nQuels programmes aident à prévenir les surdoses ?\nComment sensibiliser à l'utilisation de la naloxone ?\nLes proches doivent-ils avoir de la naloxone ?",
"url": "https://questionsmedicales.fr/mesh/D009270?mesh_terms=Hunting&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Naloxone",
"description": "Comment administrer la naloxone ?\nQuelle est la posologie recommandée de naloxone ?\nLa naloxone peut-elle être administrée par des non-professionnels ?\nCombien de temps dure l'effet de la naloxone ?\nQue faire après l'administration de naloxone ?",
"url": "https://questionsmedicales.fr/mesh/D009270?mesh_terms=Hunting&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Naloxone",
"description": "Quelles complications peuvent survenir après une surdose ?\nLa naloxone peut-elle causer des complications ?\nQuels sont les risques d'une surdose répétée ?\nComment gérer les complications post-surdose ?\nLes complications de la naloxone sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D009270?mesh_terms=Hunting&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Naloxone",
"description": "Quels sont les facteurs de risque de surdose d'opioïdes ?\nL'âge influence-t-il le risque de surdose ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'utilisation de plusieurs substances augmente-t-elle le risque ?\nLes problèmes de santé mentale sont-ils un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D009270?mesh_terms=Hunting&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une surdose d'opioïdes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur des signes cliniques comme la dépression respiratoire et la confusion."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer une surdose ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins peuvent mesurer les niveaux d'opioïdes, mais l'évaluation clinique est primordiale."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une surdose d'opioïdes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent somnolence extrême, respiration lente et pupilles constrictes."
}
},
{
"@type": "Question",
"name": "Quand utiliser la naloxone en cas de surdose ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La naloxone doit être administrée dès que des signes de surdose sont observés."
}
},
{
"@type": "Question",
"name": "La naloxone est-elle efficace pour tous les opioïdes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est efficace pour la plupart des opioïdes, mais moins pour certains comme le fentanyl."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une surdose d'opioïdes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent somnolence, confusion, respiration ralentie et perte de conscience."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une dépression respiratoire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une respiration lente, superficielle ou absente est un signe de dépression respiratoire."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la naloxone ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des symptômes de sevrage chez les utilisateurs d'opioïdes."
}
},
{
"@type": "Question",
"name": "La naloxone provoque-t-elle des effets immédiats ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la naloxone agit rapidement, souvent en quelques minutes après l'administration."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent que la naloxone fonctionne ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une amélioration de la respiration et de la conscience indique que la naloxone est efficace."
}
},
{
"@type": "Question",
"name": "Comment prévenir les surdoses d'opioïdes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éduquer sur l'utilisation sécuritaire des opioïdes et fournir des alternatives non opioïdes."
}
},
{
"@type": "Question",
"name": "La naloxone est-elle disponible sans ordonnance ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la naloxone est souvent disponible sans ordonnance dans de nombreux pays."
}
},
{
"@type": "Question",
"name": "Quels programmes aident à prévenir les surdoses ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes de distribution de naloxone et d'éducation sur les opioïdes existent."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser à l'utilisation de la naloxone ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information et des formations sur la naloxone peuvent sensibiliser le public."
}
},
{
"@type": "Question",
"name": "Les proches doivent-ils avoir de la naloxone ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir de la naloxone à portée de main peut sauver des vies en cas de surdose."
}
},
{
"@type": "Question",
"name": "Comment administrer la naloxone ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "La naloxone peut être administrée par injection intramusculaire ou par spray nasal."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie recommandée de naloxone ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dose initiale est généralement de 0,4 à 2 mg, répétée toutes les 2-3 minutes si nécessaire."
}
},
{
"@type": "Question",
"name": "La naloxone peut-elle être administrée par des non-professionnels ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la naloxone peut être administrée par des témoins ou des proches en cas d'urgence."
}
},
{
"@type": "Question",
"name": "Combien de temps dure l'effet de la naloxone ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'effet de la naloxone dure généralement de 30 à 90 minutes, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Que faire après l'administration de naloxone ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Après administration, il est crucial d'appeler les services d'urgence pour une évaluation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une surdose ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions cérébrales dues à l'hypoxie et des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "La naloxone peut-elle causer des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent survenir, notamment des symptômes de sevrage chez les utilisateurs d'opioïdes."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une surdose répétée ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les surdoses répétées augmentent le risque de dommages permanents et de décès."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications post-surdose ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une prise en charge médicale rapide est essentielle pour traiter les complications post-surdose."
}
},
{
"@type": "Question",
"name": "Les complications de la naloxone sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares, mais peuvent survenir, surtout chez les utilisateurs réguliers d'opioïdes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de surdose d'opioïdes ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation d'opioïdes, l'usage de mélanges de drogues et des antécédents de dépendance."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de surdose ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes adultes et les personnes âgées sont souvent à risque accru de surdose."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un historique familial de dépendance peut augmenter le risque de surdose."
}
},
{
"@type": "Question",
"name": "L'utilisation de plusieurs substances augmente-t-elle le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le mélange d'opioïdes avec d'autres dépresseurs du système nerveux central augmente le risque."
}
},
{
"@type": "Question",
"name": "Les problèmes de santé mentale sont-ils un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les troubles de santé mentale peuvent augmenter le risque de dépendance et de surdose."
}
}
]
}
]
}
Research and evidence-based medicine (EBM) education are important elements of emergency medicine (EM) residency training; however, curricular time is limited and integrating novel strategies to engag...
A nine-station escape room-scavenger hunt was designed around educational content including (1) predictive statistics and diagnostic test characteristics, (2) interpretation of data and statistical an...
Postactivity assessments were grounded in Kirkpatrick's model and focused on participants' reactions, learning, and behavior. Participants reported high levels of satisfaction (100% [21/21] "satisfied...
This practical, team-based curriculum was found to be a successful way to engage residents with research methodology and EBM content. This curriculum is feasible for both in-person and virtual formats...
Between 2016 and 2023, a cross-sectional study was conducted in the central region of Portugal in order to better understand the epidemiology and public health risks resulting from the handling and co...
In the first issue of Graefe's Archive from 1854, Albrecht von Graefe wrote about glaucoma. Glaucoma comes from the Greek word "glaukos," gleaming, which was first used by Homer around 800 BCE. Since ...
Virological non-suppression is a critical factor in driving HIV transmission rates, yet there is limited data available on the determinants of this phenomenon, particularly in fishing communities wher...
We conducted a cross-sectional study among all adult males (≥15 years) living with HIV who were resident within the fishing communities, and in care for atleast 6 months at the six health facilities o...
413 participants were studied and 379 (91.8%) were interviewed. The participant's average age (SD) was 40 (10.7) years and 70.5% (267/379) were engaged in the fishing business. The prevalence of virol...
Virological non-suppression among people living with HIV in fishing communities along the shores of Lake Albert is alarmingly high, exceeding the UNAIDS threshold of 10% by two-fold. Several key deter...
The spatial-temporal variation of the impact of political and social factors such as (Fishing Moratorium, Marine Protected Areas, New Year, and COVID-19) on fishing activities offshore was evaluated b...
Discarded fishing gear (DFG) comprises most of the plastic in the North Pacific Ocean and causes environmental and economic losses. Building evidence on the material construction of fishing gear types...
The atlatl is a handheld, rod-shaped device that employs leverage to launch a dart, and represents a major human technological innovation. One hypothesis for forager atlatl adoption over its presumed ...